Insider Moves: Humacyte, Aeva, Copart, Transdigm, Rockwell
Humacyte Challenges FDA Petition Amidst Controversy
Humacyte Statement on Recent Attacks
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $8
$HUMA Stock Is up 2% Today. Here's What We See in Our Data.
Insider Moves: Paychex, Summit, EXp, Humacyte, Williams-Sonoma
Humacyte Independent Chairman of the Board Acquires 121% More Stock
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $5
Buy Rating on Humacyte: Long-Term Growth Potential and Symvess Launch Optimism
Top Directors Make Bold Moves With Humacyte Stock Purchases!
Insider Purchase: Director at $HUMA Buys 50,000 Shares
Express News | Humacyte Inc : Piper Sandler Cuts Target Price to $3 From $6
10-K: FY2024 Annual Report
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $17
Humacyte Analyst Ratings
Humacyte's Symvess Gains FDA Approval and Launches
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript Summary
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $8
Humacyte Shares Tumble 10% as Q4 Loss Narrows but Revenue Remains Elusive
BTIG Adjusts Price Target on Humacyte to $8 From $10, Maintains Buy Rating